Cell surface receptor expression patterns in osteosarcoma

Cancer

Volumn 118, Issue 3, 2012, Pages 740-749

  Hassan, Sheref E ^a,b   Bekarev, Mikhail ^b   Kim, Mimi Y ^b   Lin, Juan ^b   Piperdi, Sajida ^a,b   Gorlick, Richard ^a,b   Geller, David S ^a,b  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

flow cytometry; IGF 2R; osteosarcoma; surface receptors; targeted therapy

Indexed keywords

CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; INSULIN LIKE GROWTH FACTOR RECEPTOR 2; INSULIN RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN ANTIBODY; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; OSTEOSARCOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84856220447     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26339     Document Type: Article

References (32)

1. Mirabello L, Troisi RJ, Savage SA,. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115: 1531-1543.
2. Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009; 69: 2443-2452.
3. Chou AJ, Geller DS, Gorlick R,. Therapy for osteosarcoma: where do we go from here? Pediatric Drugs. 2008; 10: 315-327.
4. Alvarez RH, Valero V, Hortobagyi GN,. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010; 28: 3366-3379.
5. Stegmeier F, Warmuth M, Sellers WR, Dorsch M,. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther. 2010; 87: 543-552.
6. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010; 375: 1030-1047.
7. Tabernero J,. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007; 5: 203-220.
8. Palazzo A, Iacovelli R, Cortesi E,. Past, present and future of targeted therapy in solid tumors. Curr Cancer Drug Targets. 2010; 10: 433-461.
9. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
10. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N,. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol. 2010; 28: 3248-3255.
11. Viereck V, Siggelkow H, Pannem R, Braulke T, Scharf JG, Kubler B,. Alteration of the insulin-like growth factor axis during in vitro differentiation of the human osteosarcoma cell line HOS 58. J Cell Biochem. 2007; 102: 28-40.
12. MacEwen EG, Kutzke J, Carew J, et al. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis. 2003; 20: 421-430.
13. Bruchim I, Attias Z, Werner H,. Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets. 2009; 13: 1179-1192.
14. Sowers R, Wenzel BD, Richardson C, et al. Impairment of methotrexate transport is common in osteosarcoma tumor samples. Sarcoma. 2011; 2011: 834170.
15. Pavelic J, Matijevic T, Knezevic J,. Biological & physiological aspects of action of insulin-like growth factor peptide family. Indian J Med Res. 2007; 125: 511-522.
16. Pavelic K, Kolak T, Kapitanovic S, et al. Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol. 2003; 201: 430-438.
17. Savage SA, Woodson K, Walk E, et al. Analysis of genes critical for growth regulation identifies insulin-like growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1667-1674.
18. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010; 54: 921-926.
19. Wang Y, Lipari P, Wang X, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther. 2010; 9: 410-418.
20. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008; 112: 2119-2129.
21. Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer. 2009; 115: 5243-5250.
22. Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008; 50: 254-258.
23. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009; 27: 3148-3153.
24. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999; 17: 2781-2788.
25. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE,. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol. 2003; 25: 27-32.
26. Children's Oncology Group. Chemotherapy with or without trastuzumab in treating patients with metastatic osteosarcoma. Bethesda, MD: National Cancer Institute; 2000. Accessed March 3, 2011.
27. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000; 6: 572-577.
28. Cantiani L, Manara MC, Zucchini C, et al. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res. 2007; 67: 7675-7685.
29. Oda Y, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi M,. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol. 2000; 31: 709-716.
30. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ,. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-280.
31. Levitzki A,. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 2005; 65: 581-586.
32. Yamasaki Y, Miyoshi K, Oda N, et al. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res 2001; 88: 630-636.